Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Net Cash Flow (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Net Cash Flow for 13 consecutive years, with -$96.9 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 26.94% to -$96.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $98.8 million through Dec 2025, up 1834.78% year-over-year, with the annual reading at $98.8 million for FY2025, 1834.78% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$96.9 million at Madrigal Pharmaceuticals, down from $109.5 million in the prior quarter.
  • The five-year high for Net Cash Flow was $522.6 million in Q1 2024, with the low at -$261.9 million in Q3 2024.
  • Average Net Cash Flow over 5 years is $7.5 million, with a median of -$3.6 million recorded in 2021.
  • The sharpest move saw Net Cash Flow soared 2209.33% in 2022, then plummeted 3729.49% in 2023.
  • Over 5 years, Net Cash Flow stood at -$12.9 million in 2021, then skyrocketed by 2209.33% to $272.2 million in 2022, then plummeted by 86.09% to $37.9 million in 2023, then crashed by 450.41% to -$132.7 million in 2024, then grew by 26.94% to -$96.9 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$96.9 million, $109.5 million, and $2.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.